



## News Release

### **Suven at Alzheimer's Association International Conference (AAIC) in London**

**HYDERABAD, INDIA (July 14, 2017)**- Suven is exhibiting and presenting several exciting new results and data presentations from Suven's portfolio of investigational neuroscience **New Chemical Entities (NCEs)** are being presented at **Alzheimer's Association International Conference (AAIC)** being held in London, England starting July 16th to 19th, 2017.

**AAIC is the world's largest conference of its kind, where thousands of international investigators, clinicians, researchers and care providers will gather to share the latest study results, theories and discoveries bringing the world closer to breakthroughs in dementia science.**

Alzheimer's disease (AD) is a global Epidemic and AD is one of the scourges of modern day health care. **47 million people worldwide are affected by Alzheimer's disease costing \$604 billion per year.** Worldwide 59 % of people incorrectly believe that Alzheimer's disease is a typical part of Aging. **Alzheimer's is not just a memory loss as everyone thinks but Alzheimer's kills.** Today, there is a worldwide effort under way to find ways to treat the disease, delay its onset, and prevent it from developing and this is where Suven is focusing on developing drugs for the treatment of this debilitating disease.

**Suven has excellent portfolio of new molecules through three mechanisms of action using 5-HT<sub>6</sub>, 5-HT<sub>4</sub> and H<sub>3</sub> receptors for the symptomatic treatment of cognitive impairment in Alzheimer's disease but also possibly useful in reducing the disease progression.** Suven scientists are presenting pre-clinical and clinical data on these molecule and other NCEs on memory related disorders, major depressive disorder and pain.

#### **About Suven Life Sciences**

Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies using GPCR targets. Suven has 4 clinical stage compounds, a Phase 2 undergoing SUVN-502, Phase 2 ready SUVN-G3031, Phase 1 completed SUVN-D4010 for Alzheimer's disease and Schizophrenia. SUVN-911 is the 4th developmental molecule from Suven's drug discovery pipeline for Major Depressive Disorder (MDD) which is undergoing Phase 1 clinical trial in USA.

In addition to these clinical compounds the Company has nine (9) internally-discovered therapeutic drug candidates currently in various stages of pre-clinical development targeting conditions such as ADHD, dementia, depression, Huntington's disease, Parkinson's disease and pain.

For more information please visit our Web site at <http://www.suven.com>

#### **Risk Statement:**

***Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future***

*circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive;*